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Abstract
Parenteral use of drugs; such as opiates exert immunomodulatory effects and serve as a cofactor in the progression of HIV-1
infection, thereby potentiating HIV related neurotoxicity ultimately leading to progression of NeuroAIDS. Morphine
exposure is known to induce apoptosis, down regulate cAMP response element-binding (CREB) expression and decrease in
dendritic branching and spine density in cultured cells. Use of neuroprotective agent; brain derived neurotropic factor
(BDNF), which protects neurons against these effects, could be of therapeutic benefit in the treatment of opiate addiction.
Previous studies have shown that BDNF was not transported through the blood brain barrier (BBB) in-vivo.; and hence it is
not effective in-vivo. Therefore development of a drug delivery system that can cross BBB may have significant therapeutic
advantage. In the present study, we hypothesized that magnetically guided nanocarrier may provide a viable approach for
targeting BDNF across the BBB. We developed a magnetic nanoparticle (MNP) based carrier bound to BDNF and evaluated
its efficacy and ability to transmigrate across the BBB using an in-vitro BBB model. The end point determinations of BDNF
that crossed BBB were apoptosis, CREB expression and dendritic spine density measurement. We found that transmigrated
BDNF was effective in suppressing the morphine induced apoptosis, inducing CREB expression and restoring the spine
density. Our results suggest that the developed nanocarrier will provide a potential therapeutic approach to treat opiate
addiction, protect neurotoxicity and synaptic density degeneration.
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Introduction
Drug abuse is one of the major concerns of present United
States. Drugs of abuse such as opiates, cocaine, methamphetamine
are frequently being used by individuals infected with HIV-1 [1].
Epidemiological data demonstrate that opioid abuse is a risk factor
for HIV-1 infection and progression to AIDS and other
neurodegenerative changes [2]. In recent years, the incidence of
HIV-1 infection has increased in drug abusing populations [3].
HIV and most abused drugs (morphine, heroine, etc) target areas
in brain such as basal ganglia and cortex that are rich in
opioidergic receptors [4].
Though opiates, especially morphine and heroin are known to
exert their effects through m-opiate receptor, the exact mechanism
by which opiates act as a cofactor for HIV infection is not clear.
However, it is reported that m opioid ligands act synergistically
with HIV proteins (tat; transactivator and gp120) to increase the
receptors necessary for the transmission of the virus and potentiate
the HIV-related neurotoxicity [5]. Opiates also have been shown
to induce apoptosis of neuronal cells, microgila, macrophages and
monocytes. Apoptosis of neuronal cells, involved in brain cell
death, accompany neurodegenerative disorders, such as Alzhei-
mer’s disease and Parkinson’s disease [6,7,8]. Therefore, the need
to protect neuronal cells against the toxic effect of drugs of abuse
using neuroprotective agents is of therapeutic importance.
Many of the drugs aimed at treating different CNS related
diseases are not very effective to do so in the brain because of the
impenetrability of these drugs across blood brain barrier (BBB) [9].
The BBB is a major physiological barrier that restricts the
transport of most small hydrophilic molecules and macromolecules
from the cerebrovascular circulation into the brain. The selective
permeability of the BBB is due to the distinct morphology and
enzymatic properties of endothelial cells that enable them to form
complex tight junctions with minimal endocytic activity. This
provides a physiological barrier that limits the transport of many
blood-borne elements such as macromolecules and circulating
leukocytes to the brain [10,11].
Brain derived neurotropic factor (BDNF), a member of
neurotrophic factor family is one of the most powerful neuropro-
tective agents for those neurons that degenerate in HIV associated
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Dementia (HAD) [12,13,14]. BDNF has been effective in
preventing gp120-mediated toxicity in in-vitro and in-vivo conditions
[15,16], increasing survival of dopaminergic neurons of the
substantia nigra after 6-OH-dopamine or 1-methyl-4-phenyl-
1,2,3,6 tetrahydropyridine (MPTP) lesions [17,18], protecting
serotonergic neurons against the neurotoxin p-chloroamphetamine
[19], and rescues cortical neurons from stroke-mediated apoptotic
cell death [20]. These results provide the rationale for using BDNF
experimentally to rescue neurons, promote regeneration of
synaptic connections and enhance neuronal plasticity in the brains
of drug abusers. Therefore, use of a neuroprotective agent such as
BDNF in addition to a m-opioid receptor antagonist could be of
therapeutic benefit in the treatment of opiate addiction [14].
However, the major problem with options using BDNF is its
inability to cross the BBB [21,22] and hence the transport of drugs
across BBB remains a challenge.
In recent years, advent of nanotechnology has stimulated the
development of innovative systems for the delivery of drugs and
diagnostic agents [23]. A significant research exploring nanocar-
rier drug delivery systems for crossing the BBB has focused on the
delivery of anticancer drugs to brain tumors. More recently, the
magnetic nanoparticles have attracted significant importance in
biomedical applications and have been increasingly used as carrier
for binding proteins, enzymes, or drugs. We and others have also
previously reported successful immobilization of several clinically
and biotechnologically important proteins and enzymes onto
magnetic nanoparticles [24]. In the present study, we hypothesized
that by binding to a magnetically guided nanocarrier, the
impermeability of BBB by free BDNF can be overcome. We
carried out the binding of BDNF with magnetic nano particle
(MNP) and studied the efficacy and ability to cross BBB.
Materials and Methods
Ethics Statement
Buffy coat was purchased from the community blood bank, for
which ethics committee approval is not needed. However, the
NIH grant which funded this work has institutional IRB approval
(#013009-00).
Preparation of Magnetic Nanoparticles
Magnetic nanoparticles were prepared by coprecipitating of
Fe2+ and Fe3+ ions in alkaline solution and treating under
hydrothermal condition as described earlier [25]. Hundred
millilitres solution of 1 M FeSO4?7H2O and 2M FeCl3 (Sigma)
were thoroughly mixed and added to 8 M ammonium hydroxide
(Sigma) with constant stirring at 25uC. The resultant black
magnetite particles were washed repeatedly with hot distilled water
to remove impurity ions such as chlorides and sulphates and
dispersed in Tris-EDTA buffer (pH 7.5). The yield of precipitated
magnetic nanoparticles was determined by removing known
aliquots of the suspension and drying to a constant mass in an
oven at 60uC. Finally, the particles were dispersed in TE buffer at
a suspension concentration of 10 mg/ml. The particles were
characterized for size using transmission electron microscopy
(TEM).
Binding of BDNF with Magnetic Nanoparticles
For the binding experiment, different ratios of magnetic
nanoparticles and BDNF (1:0.05, 1:0.01, 1:0.015, 1:0.02,
1:0.025, 1:0.03, 1:0.35) were mixed in TE buffer pH 7.5, followed
by incubating the mixture on a shaker (100 rpm) for 3 hrs at room
temperature. After incubation, the magnetic particles bound with
BDNF were attracted by application of an external magnetic field.
The supernatant containing the unbound BDNF was collected and
the pellet was resuspended in appropriate volume of TE buffer
pH 7.5 and stored at 2uC to 8uC until further use.
BDNF ELISA
The binding efficiency (mg BDNF/mg of magnetic nanoparti-
cles) was determined by measuring the amount of BDNF in the
unbound fraction by ELISA (BDNF Kit from R&D Systems,
Minneapolis, MN, USA) as per manufacturer’s recommendation.
The amount of BDNF bound to the magnetic nanoparticles was
calculated from the difference between the total BDNF added and
unbound BDNF measured in the supernatant.
Preparation of Peripheral Blood Mononuclear Cells
(PBMC)
PBMCs were isolated from buffy coat, procured from the
community blood bank, by standard, density gradient centrifuga-
tion as previously described [26,27]. Briefly, leukopack was diluted
by adding five volumes of phosphate-buffered saline (PBS) and
overlaid over histopaque (Sigma Aldrich, St. Louis, MO). The
samples were centrifuged at 1200 g for 20 min at room
temperature. PBMCs were carefully retrieved from the interface,
washed twice with PBS and resuspended in RPMI-1640.
Apoptosis Measurement
PBMC (1X106 cells/ml) were treated with morphine (1027 M)
for 48 hrs. Cells were treated with free BDNF and MNP-BDNF
(BDNF dose; 10, 50 & 100 ng/ml) 12 hr before morphine
treatment. At the termination of morphine treatment, cells were
washed twice with cold PBS and then resuspended in 1X binding
buffer at a concentration of 16106 cells/ml. 100 ml from this is
added to a 5 ml FACS tubes, followed by incubation with 5 ml
each of Annexin V and 7-AAD (BD Biosciences) for 15 minutes at
RT in the dark. After incubation, 400 ml of 1X binding buffer is
added to each tube, mixed gently and analyzed by FACScalibur
within 1 hr. The untreated cells, which served as control, is used
for defining the basal level of apoptotic and dead cells. The
percentage of cells that have been induced to undergo apoptosis is
then determined by subtracting the percentage of apoptotic cells in
the untreated population from percentage of apoptotic cells in the
treated population. Cells treated with camptothecin for 5 hrs at
37uC is used as positive control.
Toxicity
Live/Dead dye (ViViD; Invitrogen) was resuspended in DMSO
as directed by kit and diluted 1:1,000 in FACS buffer. PBMC
treated MNP-BDNF and MNP were washed with 1X with FACS
buffer and incubated for 15 minutes with 50 ml of diluted dead cell
discrimination dye on ice in the dark. Cells were then washed 2X
with FACS buffer and analyzed by flowcytometry.
In-vitro BBB Preparation
The BBB model was established according to the procedure
described earlier [28]. The BBB model consisted of 2-
compartment wells in a culture plate with the upper compart-
ment separated from the lower by a cyclopore polyethylene
terephthalate membrane (Collaborative Biochemical Products,
Becton Dickinson, San Jose, CA) with a pore diameter of 3 mm.
In a 24-well cell culture insert (surface area 0.3 cm 2), primary
human brain microvascular endothelial cells (BMVEC; 16 105)
were grown to confluency on the upper side while a confluent
layer of human astrocytes (AM) were grown on the underside.
BMVEC and AM were procured from Sciencell Research
Nanocarrier Bound BDNF for Neuroprotection
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Laboratories, Carlsbad, CA. Intactness of the BBB was judged
by measuring the trans endothelial electrical resistance (TEER)
using Millicell ERS microelectrodes (Millipore) after 6 days of
culture. A mean TEER value of 150 to 200 ohms/cm2 cell
culture insert is consistent with the formation of the BBB. The
BBB model was used for experiments at least 6 days after cell
seeding.
CREB
Total RNA was isolated using RNAeasy kit (Qiagen) as per
the manufacturer’s protocol. Total RNA (100 ng) was converted
into cDNA. CREB mRNA was measured by real-time
quantitative reverse transcription-polymerase chain reaction
(RT-PCR) using SYBR green master mix from Stratagene (La
Jolla, CA) using the Stratagene 3000 instrument that detects
and plots the increase in fluorescence versus PCR cycle number
producing a continuous measure of PCR amplification. Relative
expression of mRNA species was calculated using the compar-
ative CT method [29]. All data were controlled for quantity of
RNA input by performing measurements on an endogenous
reference gene, b-actin. In addition, results on RNA from
treated samples were normalized to results obtained on RNA
from the control, untreated sample.
DiI staining for Measurement of Spine Density and Size
Human neuroblastoma SK-N-MC cells were obtained from
ATCC. SK-N-MC cells were grown in Eagle’s minimal essential
medium (MEM) containing 10% fetal bovine serum (FBS),
5 mM sodiumpyruvate, 100 units/ml penicillin, and 100 mg/ml
streptomycin at 37˚C with 5% CO2. SK-N-MC cells were
grown onto 22 mm650 mm glass coverslips placed in a petri-
dish. Cells were treated with morphine for 48 hrs. Cells were
treated in respective wells with either free BDNF or MNP-
BDNF for 12 hrs before morphine treatment. Cells were fixed
in 4% Formaldehyde in PBS for 30 min at room temperature.
The fluorescent membrane tracer 1,19-Dioctadecyl-3,3,39,39-
tetramethylindocarbocyanine perchlorate (DiI; 5 mg/ml in PBS)
was directly added onto the fixed cultures and allowed to
incubate for 60–90 min at room temperature. The coverslips
were placed at 4˚C in small petri dishes containing PBS and
allowed for 6–12 hr for transport of the dye before confocal
microscopy.
Confocal Microscopy
Confocal images were obtained using TCS SP2 confocal laser
scanning microscope (Leica Microsystems, Germany) at 488 nm
(100%) illusion of an argon-ion laser using 606 oil immersion
objectives with high numeric aperture and 2.56 confocal
electronic zoom settings to visualize individual cells and dendrites.
Twenty Optical serial sections of 0.14 mm/section (2.8 mm total)
through the cells and reconstructed to yield complete ‘‘three
dimensional’’ images of individual cells in focus. ImageJ software
program was used to quantify DiI-labeled cells. Dendritic
segments were chosen randomly from the apical and basal regions
and at least one soma’s length away from the cell soma. The spine
density is defined as the number of spines per unit length [30]. The
length of randomly selected dendritic segment was measured, the
number of spines along that length was counted and spine density
was calculated by dividing the total number of spines by dendrite
length, as expressed as spines/10 mm.
Statistical Analysis
Data were expressed as mean6SEM of triplicate values for each
experiment. Student’s t-test was used to compare means of two
groups using Prism (GraphPad; San Diego, CA). P,0.05 was
considered significant.
Results
TEM imaging of MNP was performed to confirm the particle
size, obtain the distribution and observe general morphology of
the particles. TEM examination of prepared MNP revealed the
mean particle size to be 60 nm (figure 1). The particles were
uniform in distribution and mostly spherical in shape.
After the characterization of MNP is done, we prepared a
formulation of MNP carrying BDNF. Efficiency of BDNF binding
to MNP was calculated by using different ratios of MNP and
BDNF (1:0.05, 1:0.01, 1:0.015, 1:0.02, 1:0.025, 1:0.03, 1:0.35) in
TE buffer. Data given on figure 2 represents the binding isotherm
of BDNF binding to MNP. The binding efficiency (mg BDNF/mg
of magnetic nanoparticles) was determined by measuring the
amount of BDNF in the unbound fraction by ELISA. The
difference between the total BDNF added and unbound BDNF in
the supernatant was used to calculate the amount of BDNF bound
to the magnetic nanoparticles. The binding efficiency was in the
range of 177 mg of BDNF bound per mg of MNP in 3 hours,
which correspond to approximately 70% binding of BDNF to
MNP. This shows that BDNF was effectively bound to MNP.
After the binding efficiency was calculated, further experiments
were carried out to check whether BDNF activity is retained after
immobilization by direct binding to MNP. Our aim was to
evaluate and compare if the efficiency of bound BDNF is similar to
free BDNF. Since BDNF has been shown to prevent apoptosis in
different cells including brain cells [31], we wanted to check the
efficiency of nanofurmulation by evaluating its ability to suppress
apoptosis induced by morphinein PBMC. As expected, morphine
(1027M) induced apoptosis (55%) in PBMC compared to
untreated cells (p = 0.006) as shown in figure 3A. We saw that
BDNF pretreatment could suppress morphine induced apoptosis
in dose dependent fashion; optimum response being at 50 ng/ml
(p = 0.019). Based on this response, for our further experiments,
we used 50 ng/ml concentration of BDNF. Next, we wanted to
evaluate if MNP-BDNF formulation is as effective as free BDNF
and can revert the morphine induced apoptosis. The results
showed that BDNF bound to MNP also reversed the morphine
induced effect (p = 0.014; figure 3B), suggesting that MNP-BDNF
was equally effective as free BDNF in suppressing apoptosis, which
supports the hypothesis that binding of MNP did not interfere with
the enzymatic activity of BDNF.
Before proceeding into further experiments, we wanted to make
sure that the MNP or MNP-BDNF formulation is not toxic to the
cells, and evaluated the cytotoxicity potential of the nanoformula-
tion by flow cytometry using live/dead fixable dead cell stain,
ViViD. It was clear from results that either of them did not result
in a significant decrease in the viability of cells. Approximately,
80–90% of cells were live (Figure 4), indicating that either MNP
alone or MNP-BDNF was not toxic to cells.
In order to reconfirm the effectiveness of MNP-BDNF, we
carried out additional experiment to check the effect of MNP-
BDNF on CREB expression in astrocytes. It has been previously
shown that BDNF augments CREB expression [32], which is
known to be a player in memory. CREB functions in long-term
neuronal plasticity and enhances memory consolidation. We
checked the CREB expression in astrocytes treated with BDNF. In
agreement with previous reports [32], we found a significant
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increase in CREB expression with BDNF (TAI = 2.460.25,
p = 0.033) as shown in figure 5A. Similar to free BDNF, MNP
bound BDNF also induced significant CREB expression in
astrocytes in (TAI = 2.4360.27; p = 0.007). Expression level of
CREB was comparable with free and MNP bound BDNF, which
again supports our previous finding that free and bound BDNF
have comparable efficacy.
When astrocytes were treated with morphine, it resulted in
significant down regulation of CREB (TAI = 0.53360.03;
p = 0.0004; Figure 5B), which is also in consistent with previous
reports [29]. Further, we treated astrocytes with free or bound
BDNF 12 hrs before treatment with morphine and checked
CREB expression. We found that treatment with BDNF resulted
in reversal of morphine induced down regulation of CREB.
Moreover, similar to the previous experiment, both free
(TAI = 1.2560.03; p = 0.008) and bound BDNF
(TAI = 1.25360.06; p = 0.03) were effective in reversing morphine
induced down regulation of CREB respectively.
Since our previous results showed that MNP-BDNF is as
effective as free BDNF in its activity, our next aim was to study if
MNP bound BDNF is able to cross the BBB, and if it crosses the
BBB, whether it retains its efficiency after crossing the membrane.
For this, we set up an in-vitro BBB model. We placed MNP bound
BDNF or free BDNF on the upper chamber of BBB and allowed
them to pass through the BBB under the influence of a magnet
placed in the basal side and evaluated the expression of CREB on
astrocytes on the basal side of BBB. Culture treated with BDNF
alone did not induce any change in CREB expression in astrocytes
in the basal side. Whereas culture treated with MNP-BDNF
showed an upregulation of CREB (TAI = 1.6760.12; p = 0.007,
figure 6). This result confirmed that unlike free BDNF, BDNF
bound to MNP is able to cross BBB and is effective in its function.
Figure 1. TEM micrograph of magnetic nano particles. The average particle size is , 60 nm.
doi:10.1371/journal.pone.0062241.g001
Figure 2. Binding isotherm for BDNF on MNP. Ratios of 1:0.05,
1:0.01, 1:0.015, 1:0.02, 1:0.025, 1:0.03, 1:0.35 of MNP and BDNF were
used for 3 hrs. Binding efficiency (mg BDNF/mg MNP) was calculated by
ELISA.
doi:10.1371/journal.pone.0062241.g002
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We also evaluated the amount of BDNF transported across BBB
to understand the efficacy of MNP to transport BDNF across BBB.
We measured the concentration of BDNF in the basal portion of
BBB, and calculated the percentage of BDNF transported through
BBB. From the results, it was clear that approximately 73% of the
MNP bound BDNF was able to transport across BBB. In addition,
to confirm that passage of MNP-BDNF through BBB did not
affect the BBB, intactness of membrane was confirmed by TEER
reading. It was clear from the TEER reading that passage of
MNP-BDNF through BBB did not interfere with integrity of the
membrane; 280.4 vs 276.5 (Table 1).
Finally, we tested the ability of our nanoformulation to facilitate
the dendrite spine density. Dendritic branching and dendritic
spine densities of cells were measured by DiI staining followed by
confocal microscopy. Treatment with drugs of abuse has been
shown to decrease the dendritic spine density [33]. And BDNF has
been reported to increase dendrite numbers [34,35]. We treated
the neuronal cell line SK-N-MC, grown on glass cover slips placed
in petridishes, with MNP-BDNF 12 hrs before treatment with
morphine and evaluated the dendritic spine density. Treatment of
SK-N-MC cells with morphine resulted in significant decrease in
total dendrite area (p,0.00) and spine density (0.05560.02;
p,0.002) compared with untreated control cells (Figure 7). These
morphological changes induced by morphine was compensated by
MNP-BDNF treatment, which resulted in an increase in dendrite
branching compared to morphine treated cells (0.25860.09;
p = 0.009).
Figure 3. MNP bound BDNF is effective in suppressing the apoptosis induced by morphine. (A) Morphine induces apoptosis of human
PBMCs. PBMCs were cultured alone or with 1027 M concentration of morphine for 48 hrs. Free and bound BDNF (10, 50,100 ng/ml) were added to
respective cultures 24 hr before morphine treatment. After treatment, cells are stained with Annexin-V and 7-AAD analyzed by FACScalibur within
1 hr. The untreated cells, which served as control, is used for defining the basal level of apoptotic and dead cells. (B) Representative histogram
showing Annexin-V expression in treated cells.
doi:10.1371/journal.pone.0062241.g003
Figure 4. MNP is not toxic to the PBMC. PBMC (1X106/ml) treated
with free and bound BDNF were stained with live-dead cell
discrimination dye ViViD and analyzed by flowcytometry.
doi:10.1371/journal.pone.0062241.g004
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Discussion
Drug abuse is America’s number one enemy. Opiates, especially
morphine and heroin are known to exert their effects through m
opiate receptor [4]. Several reports have shown immunomodula-
tion in opiate using individuals [36,37]. Drugs of abuse act
synergistically with HIV proteins to potentiate HIV related
neurotoxicity and affects many functions associated with the
synaptic plasticity. About one-third of HIV infected population are
linked directly or indirectly to injection drug use, with an increase
in the incidence of HIV-1 infection in drug abusing populations in
recent years [38]. At present, there is no treatment available which
alleviate the synergistic effects of opiates and HIV, due to the same
fact that therapeutic molecules are unable to cross the BBB.
Brain-derived neurotrophic factor (BDNF), a member of the
neurotrophin family of multifunctional neurotrophic factors is
capable of regulating neuronal development and survival [39].
BDNF has been shown to prevent caspase-3-mediated apoptosis in
cerebellar granule cells in vitro [15] and in the brain in vivo [20].
This finding is especially relevant because the brains of HAD
patients show activation of caspase-3 and other pro-apoptotic
proteins [40,41]. Thus, it seems conceivable that BDNF may
prevent opiates or gp120-mediated apoptosis and its neurotrophic
activity can be extended to neuroprotection. While BDNF exhibits
neuroprotective properties in the adult CNS, it affects a variety of
events associated with neuronal plasticity during CNS develop-
ment.
Thus, there is considerable rationale for finding an adjunct
therapy to prevent neuronal degeneration and atrophy by taking
consideration the neuroprotective potential of BDNF in prevent-
ing neurotoxicity. But these large neurotrophic protein molecules
do not efficiently cross the blood–barrier into the CNS [42,43].
BBB restricts the transport of most small hydrophilic molecules
and macromolecules from the cerebrovascular circulation into the
brain, due to the distinct morphology and enzymatic properties of
endothelial cells that enable them to form complex tight junctions
with minimal endocytic activity [11,44,45]. Several approaches
are being pursued to deliver drugs across BBB which include, the
use of lipid carrier, tagging drugs to ligands that cross the BBB
through a carrier mediated transport (CMT) or receptor mediated
Figure 5. MNP bound BDNF reverses morphine induced CREB downredulation in astrocytes. (A) Morphine significantly downregulated
CREB gene expression. Astrocytes (1X106/ml) were cultured with or without morphine (1027 M) for 48 hrs; RNA was extracted, reverse transcribed,
cDNA amplified, and gene expression of CREB was determined by real-time quantitative PCR. These data are the mean 6 SD of 3 separate
experiments. (B) Astrocytes (3X106/ml) were cultured with free and bound BDNF 24 hr before morphine (1027 M) treatment. RNA was extracted,
reverse transcribed, cDNA amplified, and gene expression of CREB was determined by real-time quantitative PCR. These data are the mean 6 SD of 3
separate experiments.
doi:10.1371/journal.pone.0062241.g005
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transport (e.g. insulin, transferrin, etc) [21]. Some in-vivo strategies
for delivering neurotrophic factors to the CNS include direct
injection into the brain, viral vector upregulation, [46,47], infusion
pump-mediated delivery methods [48], trans-nasal drug delivery,
transient disruption of BBB using hyperosomotic solutions and
lipidization of small molecules. Unfortunately, these methods
presently lack practical relevance for patient treatment and the
transport of drugs across BBB still remains a challenge. Clinical
trials have demonstrated that systemic deliveries at doses that are
sufficiently high to result in therapeutic levels within the CNS
parenchyma also result in significant systemic side-effects [49]. In
order to solve the BBB drug delivery problems and to comprehend
the clinical promise of different neuroprotective factors, new
innovative technologies or need for alternative methods of drug
delivery are required.
This is where nanotechnology comes into play. A significant
research exploring nanocarrier drug delivery systems for crossing
the BBB has focused on the delivery of anticancer drugs to brain
tumors [50]. More recently, the use of magnetic nanoparticles
(MNP) has attracted significant importance in biomedical appli-
cations and this has been reported by us and others [51,52,53].
MNPs have gained significant attention due to their intrinsic
magnetic properties, which enable tracking through the radiology
cornerstone, magnetic resonance (MR) imaging. Several in-vitro
and in-vivo studies have been reported with magnetically guided
drug targeting systems [54,55]. However, no attempts have been
reported using magnetic nanocarrier drug delivery system to treat
drug abuse. The advantage of using magnetic nanoparticles
contributes to a precise delivery of drugs to the exact site (e.g.
inflammation, cancer etc.) by application of an external magnetic
field [56]. Previously our lab have reported ART bound to
magnetic nanoparticles were effective in suppressing HIV infection
and able to cross BBB [51,57]. In the present study we aimed to
investigate binding of BDNF with MNP followed by functional
effectiveness of MNP-BDNF by studying different parameters and
its ability to cross BBB.
Apoptosis, a genetically determined mechanism of programmed
cell death triggered by a variety of internal and external stimuli, is
also a pathologic feature in certain inflammatory diseases of the
brain and CNS infections, such as HAD [58]. Opiates have been
shown to induce apoptosis of all types of cells including
lymphocytes [6,7,8,59,60,61,62] through the activation of cas-
pase-3. These findings are important, considering that inhibitors of
caspase-3 activity can rescue neurons from the apoptotic cycle.
Neurotrophic factor, BDNF is a class of such inhibitors. Keeping
this fact in mind, we checked the efficacy of MNP-BDNF
formulation in suppressing the apoptosis induced by morphine
in lymphocytes. Our results confirmed that morphine induced
apoptosis in PBMC, and this effect was reversed by free BDNF.
We also found that MNP bound BDNF was also equally effective
as free unbound BDNF in suppressing the apoptosis induced by
morphine. This proved that BDNF had efficiently bound to MNP
and BDNF is still effective in its bound form.
Activation of CREB, an important factor linking the opioid-
regulated secondary messenger systems to alterations in gene
expression, is a crucial step during the consolidation of one-trial
inhibitory avoidance memory in rats [63,64,65,66,67]. Opioid
receptor stimulation by morphine leads to a decrease in the
phosphorylation of CREB [29]. BDNF exerts its role in long-term
memory (LTM) formation in the hippocampus, via the activation
of CREB in a time-dependent manner [68]. In the next
experiment, we studied the ability of MNP-BDNF to modulate
the morphine induced CREB expression in astrocytes. As
explained previously [29], CREB expression was down regulated
after morphine treatment. MNP-BDNF formulation was effective
in reversing the morphine effect on CREB expression. This
showed that nanoformulation can be used to alleviate morphine
induced effects in CNS related problems.
As previously discussed by many, the obstacle in using BDNF is
its inability to pass through BBB. So, in our further experiments,
we evaluated if MNP-BDNF formulation we prepared can be
passed through BBB. For this we used an established in-vitro
model of BBB [28,51] under the influence of an external magnetic
field. We saw that under the influence of external magnetic field
MNP-BDNF formulation could pass through BBB. Permeability of
MNP-BDNF was 3.5 folds higher than free BDNF, suggesting that
association with MNP increases the transmigration ability of
BDNF across BBB. Magnetic drug targeting of anticancer drugs to
treat brain carcinoma has also been reported [52]. In this study,
we also showed that MNP-BDNF transmigrated through BBB is
also effective in up regulating CREB expression in astrocytes on
basal side of the BBB. Free BDNF was less effective, as expected,
because of the fact that in its free form BDNF is unable to cross
BBB. Approximately 73% of total BDNF added on the top side of
BBB were able to cross BBB, when it is present in the bound form
with MNP. Moreover transport of MNP-BDNF formulation did
not interfere with BBB integrity, as indicated by TEER reading.
Numerous studies have shown that drug addiction alters the
function of the neuronal circuit, including changes in neuronal
plasticity and synaptic transmitter release [69,70,71]. Previous in-
vivo studies suggest that morphine administration produces a
persistent decrease in dendritic branching and spine density of
medium spiny neurons in the nucleus accumbens shell and
Figure 6. MNP bound BDNF efficiently crosses BBB and induces
CREB expression. Free and bound BDNF were added to the
respective wells of BBB, in the upper chamber. A weak magnet was
placed on the basal side of BBB. Astrocytes (3X106/ml) were collected
from basal side, RNA was extracted, reverse transcribed, cDNA
amplified, and gene expression of CREB was determined by real-time
quantitative PCR. These data are the mean 6 SD of 3 separate
experiments.
doi:10.1371/journal.pone.0062241.g006
Table 1. Transendothelial electrical resistance (TEER) values
before and after treatment with MNP-BDNF.
Before Treatment After Treatment
Untreated 287.669.4 286.6767.2
MNP-BDNF treatment 280.4610.4 276.5669.7
doi:10.1371/journal.pone.0062241.t001
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pyramidal cells in sensory cortex [72], decrease in both total
dendrite length and dendritic spine density of neurons in visual
cortex [33]. In agreement with these studies, we saw that
morphine treatment decreased the spine density and length,
which was reversed by MNP-BDNF treatment.
Since one of the major concerns while using nanomaterials in
medicine is that of potential toxicity, evaluating cell viability is
important for the nanoparticle application in medicine. When we
checked the viability of PBMC cultured with MNP and MNP-
BDNF by flow cytometry using a dead cell discrimination dye
(ViViD), we saw that either of them did not affect viability
suggesting that they are non-toxic to cells.
In summary all our results explain that even after binding with
MNP, BDNF retains its activity and it is as effective as free form of
BDNF. This support our hypothesis that MNP bound BDNF can
be used as therapeutic approach in drug abused population.
Through the use of an in vitro BBB model, this study has
established fundamental observation regarding the neuroprotec-
tive activity of MNP bound BDNF.
Future studies will investigate whether MNP-BDNF is neuro-
protective in vivo in animal models. Studies are also under
investigation for simultaneous binding of HIV drug and BDNF
with magnetic nanocarriers, which will help in targeting HIV
infection and drug abuse related issues simultaneously.
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